Activities Under Research Program Sample Clauses

Activities Under Research Program. ImmunoGen hereby grants to Aventis and its Affiliates, subject to Section 7.1.8 below, a co-exclusive (with ImmunoGen and its Affiliates), worldwide, royalty-free license, during the Research Program Term, with the right to grant sublicenses to Approved Subcontractors, under the ImmunoGen Intellectual Property, to conduct the Research Program in accordance with the Annual Research Plan.
Sample 1Sample 2
AutoNDA by SimpleDocs
Activities Under Research Program. Subject to the terms and conditions of this Agreement (including the license grants set forth in this Article 7 with respect to Ex-Program Products) and any applicable Burdened Technology Obligations, Aventis hereby grants to Millennium a worldwide, co-exclusive, non-royalty-bearing license during the Research Program Term, under Aventis' rights to the Aventis Ex-Program Intellectual Property and the Program Intellectual Property, to (A) identify and validate targets for the identification, evaluation, and optimization of Small Molecules [**], (B) identify Small Molecules through the use of such targets and (C) undertake Pre-EDC Research Evaluation of such Small Molecules, in each case, in the conduct of the Research Program. Such license shall further include the right to grant sublicenses to Affiliates of Millennium and to Third Parties that are approved by the Joint Research Committee.
Sample 1
Activities Under Research Program. Subject to the terms and conditions of this Agreement and any applicable [**], Amgen hereby grants to Tularik a worldwide, co-exclusive, non-royalty-bearing license during the Research Program Term, under Amgen’s rights to the Program Intellectual Property, the Amgen Background Technology and the Amgen Background Materials, to (i) identify and validate Targets for the identification, evaluation and optimization of Molecules Active against such Targets, (ii) identify Molecules Active against such Targets through the use of such Targets and (iii) undertake Pre-Clinical Research Evaluation of such Molecules, in each of (i) through (iii), in the conduct of the Research Program. Such license shall further include the right to grant sublicenses to Affiliates of Tularik and to Third Parties that are approved by the Joint Research Committee.
Sample 1
Activities Under Research Program. Aventis hereby grants to ImmunoGen and its Affiliates a co-exclusive (with Aventis and its Affiliates), worldwide, royalty-free license, with the right to grant sublicenses to Approved Subcontractors, during the Research Program Term, under the Aventis Intellectual Property and the Program Intellectual Property, to conduct the Research Program in accordance with the Annual Research Plan. Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Activities Under Research Program. Editas may (in its discretion) conduct (or have conducted) Research activities during the Research Program Term for a Collaboration RNP Complex in connection with α-β T-Cells or Other Derived T-Cells only under and in accordance with this Agreement, and subject to Juno’s Opt-In Rights hereunder. For clarity, nothing in this Section 2.1(c) is intended to limit or otherwise modify Editas’ rights to conduct activities (including research, development, manufacturing or commercialization activities) outside of the Exclusive Field, even as such activities relate to the research and development of RNP Complexes Directed to Collaboration Targets. Editas shall be responsible for research strategy and the conduct of activities under the Research Program during the Research Program Term. Notwithstanding anything to the contrary set forth herein, if any Research activities are undertaken by or on behalf of Editas or any of its Affiliates (other than in the conduct of an Existing Acquirer Program by any Acquiring Affiliate) with respect to any RNP Complex Directed to a Collaboration Target in connection with α-β T-Cells or Other Derived T-Cells in the Exclusive Field (other than with respect to any Lapsed Collaboration RNP Complexes), then such activities shall automatically be deemed to be undertaken pursuant to a Program under this Agreement.
Sample 1

Related to Activities Under Research Program

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Conduct of Research Program Each Party:

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Research Collaboration (a) GSK hereby grants to Anacor a non-exclusive, non-royalty bearing license under the GSK IP, solely as and to the extent necessary or important to conduct activities for which Anacor is responsible under the Research Plans during the Research Collaboration Term.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

Time is Money Join Law Insider Premium to draft better contracts faster.